Avoiding Pitfalls in Emerging Infectious Disease Management: Cyclospora Outbreak and Diagnostic Challenges

Cyclospora Outbreak and Diagnostic Challenges

Infectious Disease · Seminar week 15 · released July 14, 2026 · includes a discussion video

The recent rise in cyclospora outbreaks (affecting over 2,900 nationwide) has highlighted significant diagnostic challenges and treatment strategies. This seminar will…

Learning Objectives

By the end of this seminar, participants will be able to:

• Recognize the seasonal, clinical, and transmission pattern of cyclosporiasis, including prolonged or relapsing illness without international travel.
• Interpret the fast-moving 2026 outbreak counts without conflating confirmed domestic cases, travel-associated cases, state reports, and cases awaiting classification.
• Select an appropriate diagnostic strategy and operationalize either Cyclospora-containing molecular testing or targeted microscopy.
• Initiate evidence-based treatment with TMP-SMX and construct a safe plan for immunocompromised or sulfonamide-allergic patients.
• Counsel patients on realistic food-safety measures while a specific food source remains unconfirmed.
• Report cases and collect exposure details that make a diagnosis useful for public-health investigation and supply-chain traceback.

Introduction and the Current 2026 U.S. Outbreak

%%FIG0%% The central paradox of the 2026 cyclosporiasis season is that a very large outbreak has been unfolding while the numbers visible to clinicians, states, and the public have often described different slices of it. As of mid-July, the CDC Health Alert Network reported approximately 1,645 laboratory-confirmed, domestically acquired cases since May 1 across 34 states, with more than 5,100 additional cases still requiring review to determine whether they met the domestic case definition. That confirmed count was about 6.6 times the 249 cases reported nationally at the comparable point in 2025—nearly a sevenfold increase. Among the 1,645 confirmed domestic cases, 141 people, or 9%, were hospitalized and no deaths were reported. CDC’s updated domestic line list described ages 2–95 years, median 44, with 56% female. A separate travel-associated cohort reported alongside it included patients ages 14–89, median 45, with 59% female; those demographics should not be reassigned to the domestic cohort.

State data made the scale even more visible. Michigan had reported more than 2,600 cases by July 13, far above its usual annual burden, while Illinois, New York, Texas, Ohio, and other jurisdictions also reported substantial activity. These totals overlap with federal categories and differ in timing, travel-status review, and verification, so they cannot simply be added to the CDC count. More than 400 cases across Michigan, Ohio, West Virginia, and Kentucky appear epidemiologically connected. Michigan interviews identified lettuce or salad greens as an early recurring exposure, but no specific food, brand, grower, or supplier had been confirmed. Past U.S. outbreaks involved raspberries, basil, cilantro, snow peas, and lettuce or salad greens, making produce a rational focus—not proof of the current source.

MUST ACT: During the May 1–August 31 U.S. cyclosporiasis season, consider Cyclospora in persistent or relapsing watery diarrhea even when the patient has not traveled internationally. The calendar defines a surveillance season, not a biologic boundary, and cases can occur outside it.

Cyclospora cayetanensis is a coccidian protozoan parasite that infects small-intestinal epithelium. Infected people shed unsporulated oocysts that are not immediately infectious. The oocysts must mature, or sporulate, in the environment over days to weeks before they can infect another person. That lifecycle explains why direct person-to-person transmission is negligible and why contaminated water and fresh produce—especially foods eaten raw—dominate outbreak investigations. An infected food handler is not analogous to a person acutely shedding norovirus; environmental maturation must intervene.

After ingestion, the incubation period is usually about one week, with a range of roughly 2–14 days and occasionally longer. The signature syndrome is frequent, watery, nonbloody diarrhea that may improve and recur. Profound fatigue can be out of proportion to examination findings. Anorexia, weight loss, bloating, cramping, nausea, excess gas, and a low-grade fever may accompany it; vomiting is less common. Untreated illness may persist for weeks and relapse more than once. Severe dehydration, malabsorption, biliary disease, or prolonged illness is more likely in patients with impaired immunity, although substantial morbidity also occurs in otherwise healthy adults.

Teaching Point: The same biology that makes household transmission unlikely makes source identification difficult: a long incubation separates the contaminated meal from symptoms, and the implicated perishable food may be consumed or discarded before anyone recognizes a cluster.

Nuance: No deaths does not mean low impact. A 9% hospitalization proportion, weeks of diarrhea, lost work, weight loss, and recurrent care represent a major burden—and a large reporting backlog means the observed denominator is still changing.

Audience Poll: Which fact should most change your testing behavior tonight: the absence of travel, a negative routine stool study, the patient’s temporary improvement, or the nearly sevenfold seasonal increase?

The Public-Health Surveillance Gap: Detection, Characterization, and Response Capacity

The 2026 surge is not evidence that surveillance reductions created contaminated food. It is a stress test showing that surveillance architecture determines what becomes knowable, when, and whether thousands of diagnoses can become an actionable traceback before memory and product disappear. Capacity can be lost at every link.

Framework: Think of outbreak surveillance as recognize → test → report → classify → interview → cluster → traceback → communicate. A failure or delay near the beginning propagates downstream. A patient never tested is not merely an uncounted case; that patient is a missing food history, missing purchase location, and missing chance to find a shared supplier.

FoodNet and the National Notifiable Diseases Surveillance System serve different functions. FoodNet is active surveillance covering about 16% of the U.S. population. Effective July 1, 2025, CDC narrowed required reporting in its eight-pathogen program from eight organisms to Salmonella and Shiga toxin-producing Escherichia coli; reporting became optional for the other six, including Cyclospora. This removed a standardized active layer for trend and burden characterization.

FoodNet was not designed primarily to detect individual national outbreaks, and saying the change “stopped Cyclospora surveillance” is inaccurate. Cyclosporiasis remains nationally notifiable through NNDSS and reportable under most jurisdictional laws. CDC says the FoodNet change did not alter the case-report, interview, and traceback processes used here. It therefore cannot be claimed to have caused the outbreak or, by itself, explain the unknown source.

Nuance: The strongest causal statement is narrower: reduced active surveillance and diminished response capacity can slow baseline recognition, case ascertainment, detailed characterization, interviewing, data reconciliation, and communication. They affect the speed and resolution of the response more plausibly than the occurrence of the contamination itself.

The public-facing lag illustrates the problem. By July 13, CDC’s posted national tally was about 843 confirmed domestic cases based on data through July 9, while Michigan reported 2,640 cases. State reports can include cases awaiting travel interviews or national classification, yet a national dashboard below one state’s current report blurs situational awareness unless dates and definitions are explicit. The update to 1,645, with more than 5,100 pending review, exposed the reconciliation workload. These overlapping figures must not be summed.

Patient interviews are often rate-limiting. The exposure window begins up to two weeks before symptoms, and interviews may occur weeks later. Staff must ask about produce, mixed dishes, restaurants, stores, brands, travel, water, and dining companions. Delay erodes recall; receipts and packaging disappear; and perishable food is gone before testing. Michigan completed more than 1,000 interviews by July 13, demonstrating the workload. Hiring freezes, retirements, outdated systems, competing outbreaks, and reassigned staff can turn a difficult investigation into a backlog.

Cyclospora cannot be routinely cultured and rapidly fingerprinted through the mature whole-genome-sequencing pathway used for Salmonella or STEC. Targeted genotyping helps group cases but is technically complex and must be paired with interviews and traceback. Clinical panel uptake also varies, so observed incidence reflects both transmission and the geography of testing.

Some experts have called this surge “predictable and preventable,” arguing that weakened capacity forced a reactive posture. That framing appropriately highlights systemic vulnerability but should not be presented as proof that cuts caused the outbreak. CDC and other experts emphasize that FoodNet measures trends rather than functioning as the principal outbreak alarm. The balanced teaching conclusion is that epidemiologic capacity is itself a determinant of outbreak outcome: it governs how fast a source can be characterized, a product removed, and guidance issued.

MUST ACT: When surveillance is delayed, frontline clinicians must raise—not lower—their index of suspicion. Do not wait for a national count to catch up before ordering the right test, reporting a result, preserving a specimen, or documenting food purchases.

Teaching Point: Timeliness is an intervention. A diagnosis reported today can generate a usable interview; the same diagnosis reported three weeks later may arrive after both memory and product have vanished.

Audience Poll: Where is the most consequential bottleneck in your system: recognizing the syndrome, knowing what the panel contains, laboratory turnaround, mandatory reporting, or capacity to interview the patient promptly?

Diagnostic Approaches: Molecular Testing Versus Microscopy

%%FIG1%% Test for Cyclospora when watery diarrhea is persistent, recurrent, or unusually fatiguing—especially from May through August, during a regional increase, or after fresh-produce or untreated-water exposure. Travel raises risk but is not required. Weight loss, anorexia, bloating, and partial improvement followed by relapse strengthen the phenotype. Blood, high fever, peritoneal findings, shock, or marked inflammation should broaden the workup for alternative or concurrent disease.

MUST ACT: Do not write only “ova and parasites” and assume Cyclospora has been excluded. Specifically request Cyclospora testing, or order a gastrointestinal molecular panel only after verifying that the exact panel used by your laboratory includes C. cayetanensis.

Microscopy can establish the diagnosis if the laboratory uses appropriate recovery and visualization. Oocysts are spherical, approximately 8–10 micrometers, and may be sparse because shedding is low-level or intermittent. Concentration improves yield. Modified acid-fast staining is variable, from unstained or pale to pink, red, or purple; under ultraviolet microscopy, the wall autofluoresces blue or green. Routine trichrome examination or an unalerted laboratory may miss this pattern.

If targeted microscopy is the available route and the first specimen is negative, collect additional stools on separate days when suspicion remains high. That is not ritualistic “three samples for everyone”; it is a response to intermittent, relatively low-level shedding and operator-dependent detection. Tell the laboratory the clinical concern so it can use concentration, modified acid-fast staining, and/or UV fluorescence rather than treating the sample as a generic O&P examination.

Molecular diagnosis has changed the epidemiology. FDA-cleared multiplex GI PCR panels that include Cyclospora detect parasite DNA with high sensitivity, usually faster and with less operator dependence than microscopy. Simultaneous testing for other causes helps when the syndrome is nonspecific or coinfection is possible. Greater panel use has increased observed case counts by finding infections previously missed.

Nuance: “PCR panel” is not a single universal test. Panel menus differ, some narrower panels omit Cyclospora, performance depends on specimen quality and assay design, and a negative panel that lacks the target provides no information about cyclosporiasis. Ask the laboratory, not the order-entry label.

PCR may be costly or restricted and provides no susceptibility result. Interpret positives with the syndrome; multiple targets do not establish which causes symptoms. A compatible symptomatic patient with a positive Cyclospora target generally has actionable infection, and treatment need not await microscopy unless the laboratory identifies an assay concern.

Decision Point: If your hospital’s panel includes Cyclospora and returns within hours, send it on the first adequate diarrheal stool. If the panel omits the target or access is limited, order a targeted Cyclospora examination or reference-laboratory PCR and consider serial specimens. If an earlier “O&P negative” result did not use Cyclospora-specific methods, reorder correctly rather than treating that result as exclusion.

After a positive culture-independent diagnostic test, contact the laboratory and public-health department early. Jurisdictions may request a retained stool aliquot, targeted confirmation, or referral for genotyping. Preserve residual specimen when feasible; the clinical result treats the patient, while the specimen may help link the patient to a cluster. Laboratories should report according to jurisdictional requirements, but the ordering clinician should not assume every electronic interface is timely.

Teaching Point: Molecular testing is a double-edged surveillance tool. It improves patient care and raises case detection, but national visibility becomes panel-dependent: communities using a Cyclospora-containing assay appear sooner than communities where clinicians never request the target.

Audience Poll: Before tonight, could you name the manufacturer and targets on your local GI panel—and what would your backup order be if Cyclospora is absent?

Empirical and Directed Treatment: TMP-SMX, Supportive Care, and Sulfonamide Allergy

%%FIG2%% Begin with severity assessment: evaluate oral tolerance, urine output, volume status, electrolytes, and renal function as indicated. Replace fluid and potassium orally when possible and intravenously when losses are severe. Immunocompetent people may recover without therapy, but illness can last a month or longer and relapse; treatment is especially important for severe, prolonged, or immunocompromised disease.

Trimethoprim-sulfamethoxazole (TMP-SMX; co-trimoxazole) is the treatment of choice. The typical immunocompetent adult regimen is one double-strength tablet—trimethoprim 160 mg plus sulfamethoxazole 800 mg—by mouth twice daily for 7–10 days, consistent with CDC clinical guidance. Pediatric dosing for children at least two months old is based on the trimethoprim component and should follow current weight-based guidance. Obtain stool before the first dose when that can be done promptly, but do not impose a clinically harmful delay on a dehydrated, immunocompromised, or highly symptomatic patient merely to protect diagnostic purity.

Framework: Decide whether to treat empirically by integrating probability, severity, immune status, test turnaround, and follow-up reliability. A stable patient with mild illness and same-day PCR may reasonably await a result. A patient with classic relapsing watery diarrhea, substantial regional activity, worsening dehydration, and a multiday reference-laboratory delay may justify treatment after specimen collection. Exposure to “salad” alone is not enough to treat every brief diarrheal illness.

Before prescribing, review allergy phenotype, pregnancy, creatinine, potassium, and interacting drugs. TMP-SMX can cause rash, cytopenias, kidney injury, hyperkalemia, and interactions including with warfarin. Adjust for renal impairment. Pregnancy requires individualized risk-benefit assessment, particularly near term.

MUST ACT: Use the correct drug, dose, and duration. Azithromycin, metronidazole, doxycycline, albendazole, and routine broad “enteric coverage” are not reliable treatment for Cyclospora. Symptomatic improvement after nonspecific therapy does not prove eradication because the disease naturally waxes and wanes.

Patients with advanced HIV, transplantation, chemotherapy, or other major immunosuppression may require a longer course and sometimes a higher-intensity or suppressive TMP-SMX strategy. There is no universal protocol; older HIV studies used varying regimens. Individualize with infectious-disease or HIV expertise, optimize immune function, and reserve secondary suppression for selected recurrent disease with persistent profound immunosuppression.

Sulfonamide allergy exposes a major weakness: no alternative is comparably established. Clarify whether “allergy” means intolerance, a remote exanthem, anaphylaxis, or a severe delayed reaction such as Stevens-Johnson syndrome or DRESS. Never casually rechallenge a severe reaction. After a non-life-threatening reaction, specialist-supervised desensitization may be considered when TMP-SMX is necessary.

Nuance: Ciprofloxacin is an inferior fallback, not an equivalent second first-line drug. A small study in people with HIV suggested modest activity, while clinical experience in immunocompetent patients has often been disappointing. Nitazoxanide has been used, but efficacy is variable and supported by limited data. If TMP-SMX cannot be given, discuss supportive care, the urgency of treatment, desensitization eligibility, and weakly supported alternatives with an expert and the patient.

Clinical response is usually the key follow-up measure. Routine test-of-cure is generally unnecessary after complete resolution in an immunocompetent patient unless public health requests it. Persistent or recurrent symptoms should trigger reassessment of adherence, dose and duration, hydration, immune status, coinfection, and whether the original diagnosis fully explains the illness. Relapse is part of the natural history and is not synonymous with resistance.

Decision Point: If a stable patient reports a vague childhood “sulfa allergy,” do not default reflexively to ciprofloxacin. Define the reaction, assess how urgently treatment is needed, and choose among observed supportive care, specialist-guided challenge or desensitization, or a less reliable alternative.

Audience Poll: Which factor would most strongly move you from “collect and await rapid PCR” to immediate empiric TMP-SMX: ten days of illness, regional case counts, acute kidney injury from volume loss, immunosuppression, or inability to ensure follow-up?

Food Safety and Outbreak Prevention: From the Sink to the Supply Chain

%%FIG3%% Patient counseling must be honest about its limits. Rinsing produce under clean running water removes soil and reduces contamination but does not reliably eliminate tightly adherent Cyclospora oocysts. Scrub firm produce, remove damaged areas or outer leaves when appropriate, refrigerate cut produce, and keep hands and surfaces clean. Do not use soap, bleach, or unapproved disinfectants on food. “Pre-washed” is not proof of sterility.

Teaching Point: Washing is risk reduction, not sterilization. Advice that implies infection occurred because a patient “failed to wash correctly” is scientifically inaccurate and shifts responsibility away from agricultural-water quality, sanitation, processing, and distribution controls.

Cooking provides a kill step that raw produce lacks. During a local outbreak, follow current state or local recommendations; Michigan advised that heating suitable foods to at least 158°F (70°C) is the safest option and issued temporary lettuce-specific precautions while its investigation continued. National counseling should not automatically become “avoid all produce.” Fresh foods have substantial nutritional benefit, most items are not contaminated, and overly broad avoidance can cause harm. When authorities identify a product, lot, restaurant, or supplier, follow the recall or advisory precisely.

The lifecycle places prevention upstream. Environmental maturation allows contamination of irrigation or wash water, soil, equipment, and produce. Controls include safe agricultural water, worker sanitation, exclusion of fecal contamination, traceable lot codes, accurate importer and distributor records, and rapid invoice sharing. Routine chemical sanitizers may not reliably inactivate Cyclospora.

Framework: Traceback runs farm or source water → processor or packer → distributor → retailer or restaurant → patient. Investigators look for a convergence point across many apparently unrelated meals. A single ingredient may appear in salads, sandwiches, garnishes, and mixed dishes, while one distributor may serve both restaurants and grocery stores.

“Domestically acquired” is an epidemiologic classification, not a statement about where the food was grown. It means the patient was infected in the United States and lacked relevant international travel; the implicated produce could be domestically grown or imported. Previous U.S. outbreaks have involved both imported produce and products distributed through domestic supply chains. Prematurely blaming a country, grower, cuisine, or retailer can stigmatize communities, distort purchasing, and contaminate interview responses.

Nuance: Michigan’s lettuce or salad-greens signal is a hypothesis generated from interviews, not confirmation of the national source. Other foods have not been excluded, the broader U.S. season may contain multiple outbreaks, and some cases may be unrelated.

Clinicians participate in food safety by making each case traceable. Ask for purchase and consumption dates; grocery and restaurant names and locations; brands, salad-kit varieties, and loyalty accounts; delivery-app histories; dining companions; and whether packaging, leftovers, or receipts remain. Tell patients not to submit or transport food samples on their own; coordinate with public health so chain-of-custody and appropriate laboratory methods are preserved. Report promptly because a cluster becomes visible only when multiple individual histories can be compared.

MUST ACT: Pair food advice with reporting. “Wash produce” alone cannot stop a dispersed supply-chain outbreak; a timely case report and detailed purchase history may do more to prevent the next exposure.

Audience Poll: Which is the more powerful outbreak-control intervention for your confirmed patient: another generic food-safety handout, or a same-day report accompanied by a dated grocery and restaurant history?

Public-Health Communication Under Uncertainty

%%FIG4%% Communication during a source-unknown outbreak is a clinical intervention. Poor messaging can create false reassurance, produce panic, stigmatize a food or community, or discourage patients from participating in interviews. Good messaging states what is known, what remains unknown, what agencies are doing, and what the audience can do now. It also dates every number. “There are 843 cases” and “Michigan alone has 2,640 reports” sound irreconcilable until the speaker explains that one was an earlier nationally classified domestic total and the other a later state-level operational count.

Framework: Use four headings in every update: What we know; What we do not know; What is being done; What you should do. For the mid-July 2026 outbreak, what is known includes the large seasonal increase, cases in 34 states, a more-than-400-case linked cluster across four states, and a characteristic prolonged diarrheal illness. What is unknown includes the definitive food source and whether all geographic increases share one source. What is being done includes case interviews, targeted genotyping, cluster analysis, and FDA traceback. What people should do includes seeking care for prolonged watery diarrhea, requesting appropriate testing, following official product-specific advisories, and cooperating with public health.

MUST ACT: Say plainly, “No specific national source has been confirmed.” Do not convert a preliminary exposure signal into a product accusation, repeat an unofficial recall, or advise the entire public to stop eating all fresh produce.

Explain why an investigator may call. Encourage patients to reconstruct the 14 days before illness using loyalty accounts, delivery histories, receipts, calendars, photographs, and dining companions. Ask about components of mixed dishes, but use neutral prompts that do not lead patients toward a presumed source.

For clinicians and laboratories, the message is operational: consider Cyclospora without travel; verify the test target; retain specimens when requested; and report promptly. Public messages should be accessible and multilingual, distinguish prolonged watery diarrhea from brief illness, identify dehydration signs, and explain that direct spread is unlikely while routine hygiene remains important for other enteric pathogens.

Nuance: Transparent uncertainty builds trust. Correcting a stale count openly is stronger than silently replacing it, and acknowledging reporting lag is not the same as alleging concealment. Public dashboards should label data-through dates, case definitions, pending classifications, and expected lag.

Communication should also acknowledge the capacity debate accurately. Some experts describe the outbreak as predictable and preventable and view it as evidence of an overextended public-health system. Others emphasize that FoodNet was not the principal outbreak-detection channel and that NNDSS reporting continues. Both can be true: no evidence proves surveillance reductions caused contaminated food, while slower interviews, thin staffing, uneven testing, and delayed aggregation can plainly make characterization and control harder.

Teaching Point: Risk communication is not a press-office afterthought. It shapes whether clinicians test, whether patients disclose useful exposure histories, whether businesses preserve records, and whether the public follows precise guidance rather than rumor.

Audience Poll: How would you explain the 843-versus-2,640 mismatch in one sentence without minimizing the outbreak or implying the datasets are directly comparable?

Antimicrobial Stewardship Without Inventing Cyclospora Resistance

%%FIG5%% The legacy framing of this topic as “antimicrobial resistance in Cyclospora” risks teaching a phenomenon that clinical medicine cannot currently measure. There is no validated routine susceptibility test for C. cayetanensis, no established clinical breakpoint for TMP-SMX, and no demonstrated national trend of rising TMP-SMX-resistant Cyclospora that should drive bedside decisions. The figure above should therefore be interpreted as broad stewardship context, not evidence of a Cyclospora resistance curve.

Nuance: The relevant resistance concern is largely collateral and inferential. Unnecessary antibacterial exposure selects resistance in bystander bacteria and causes adverse events; it does not justify withholding effective TMP-SMX from a patient with likely or confirmed cyclosporiasis.

Diagnostic stewardship is the first antimicrobial intervention. Without a Cyclospora test, a patient may accumulate azithromycin, ciprofloxacin, metronidazole, or broad enteric therapy while the parasite remains untreated. Metronidazole is not appropriate merely because the illness is “parasitic,” and ciprofloxacin is not equivalent to TMP-SMX. Targeted testing replaces serial guessing with directed therapy.

Framework: Apply six stewardship questions: right patient, right test, right drug, right dose, right duration, right reassessment. The right patient has a compatible syndrome and epidemiologic context. The right test actually contains or visualizes Cyclospora. The right drug is TMP-SMX when not contraindicated. The right adult dose is DS 160/800 mg twice daily, usually for 7–10 days in an immunocompetent host. Reassessment confirms clinical response and revisits immune status, adherence, and competing diagnoses when the course is atypical.

Outbreak awareness should not trigger TMP-SMX for every brief diarrheal episode or lettuce exposure. Collect stool first, estimate probability, and consider turnaround. Conversely, waiting days for a send-out in a severely ill transplant recipient with a classic syndrome may cause harm. Stewardship balances diagnostic certainty against untreated disease; it is not synonymous with delay.

When a molecular panel returns positive for Cyclospora, stop redundant antibacterials unless another detected pathogen or clinical diagnosis independently requires them. Review renal dosing and interactions rather than substituting an inferior agent for convenience. A documented severe sulfonamide reaction may necessitate supportive care or an alternative with limited evidence, but ciprofloxacin should not be marketed as a “narrower” equal. In selected nonsevere allergy histories, specialist-guided evaluation or desensitization may preserve the most effective treatment.

Decision Point: A multiplex panel detects Cyclospora and enteropathogenic E. coli in a patient with classic relapsing watery diarrhea. Do not reflexively treat every target. Decide which result fits the syndrome, whether the second detection is clinically actionable, and discontinue agents that have no defined purpose.

Relapse should prompt reassessment, not a declaration of resistance. Review adherence, absorption, duration, immune status, coinfection, and noninfectious disease; repeat testing or obtain infectious-disease input when indicated. Broader antibacterial therapy without a target adds toxicity while missing the reason for recurrence.

Teaching Point: In this outbreak, stewardship means treating a protozoal infection correctly and avoiding broad antibacterial noise. Better surveillance and better stewardship share the same first step: order a test that can actually see the organism.

Audience Poll: Which stewardship error is more likely in your setting—unnecessary TMP-SMX for low-probability illness, or repeated broad-spectrum therapy because Cyclospora was never included in the diagnostic plan?

A Clinical Case: When a Negative Test and a Stale Dashboard Reassure the Team

A 46-year-old Michigan school counselor presents in July with 12 days of nonbloody watery diarrhea. She briefly improved, then relapsed with eight stools daily, profound fatigue, anorexia, bloating, nausea, and a 4-kg weight loss. She has not traveled internationally, and her spouse is well. At urgent care, bacterial culture and generic O&P were negative; azithromycin provided no benefit.

She is afebrile with mild orthostasis, dry mucosa, and nonperitoneal tenderness. Potassium is 3.2 mmol/L and creatinine is above baseline. She has no blood in stool or focal findings. The electronic dashboard still shows a national count far below local reports.

Audience Poll: What has actually been ruled out? A negative routine culture reduces the likelihood of the organisms that laboratory cultures; the generic O&P result does not reliably exclude Cyclospora unless the laboratory used specific concentration and detection methods. The stale dashboard describes delayed aggregation, not low local prevalence.

The clinician recognizes the season, relapsing phenotype, weight loss, lack of fever or blood, and regional surge. She calls the microbiology laboratory and learns that the emergency department’s multiplex GI PCR panel does include C. cayetanensis. A diarrheal stool specimen is collected before additional antimicrobial therapy; an aliquot is retained. The team gives intravenous crystalloid, replaces potassium, reassesses renal function, and confirms that the patient can drink and has reliable follow-up.

Decision Point: Treat now or await PCR? She is symptomatic and volume depleted, but immunocompetent and clinically improving after fluids; the panel is expected in four hours. Waiting for that rapid result is reasonable. If the assay were a four-day send-out, or if she were a transplant recipient with worsening losses, empiric therapy after specimen collection would be more compelling.

The PCR detects Cyclospora and no other actionable pathogen. Azithromycin is stopped. Her allergy review reveals no sulfonamide reaction, pregnancy is excluded, renal dosing is appropriate, and interacting medicines are reviewed. She receives TMP-SMX DS 160/800 mg orally twice daily, with a planned 7–10-day course, oral hydration instructions, and a 48–72-hour clinical check. She is told to return for inability to maintain hydration, syncope, oliguria, worsening pain, blood in stool, or new fever.

MUST ACT: The positive result is reported to the local health department the same day rather than left to passive electronic routing. The clinician documents symptom onset and the relevant 14-day pre-illness window, asks the laboratory to retain stool for possible public-health referral, and tells the patient why a detailed interview matters.

At first, she remembers only several salads. Neutral prompts and her grocery-app history identify dates, stores, packaged products, herbs, restaurant meals, and dining companions. One purchase overlaps with other histories, generating a lead—not proof. Investigators still need background consumption, distribution records, genotyping, and other exposures. She retains receipts and photographs but sends no food unless public health arranges collection.

Teaching Point: The clinician has done more than treat one patient. Correct test selection converted a falsely reassuring “negative O&P” into a diagnosis; same-day reporting converted the diagnosis into a timely exposure interview; and digital purchase records made the interview more reliable. In a strained surveillance system, those actions are outbreak control.

Her stool frequency falls within three days and she completes therapy without relapse; routine test-of-cure is unnecessary. Recurrence would prompt review of adherence, dose, duration, hydration, coinfection, and occult immunocompromise—not a reflex diagnosis of resistance.

Now change one feature: she is a kidney-transplant recipient with a history of TMP-SMX-associated Stevens-Johnson syndrome. TMP-SMX rechallenge or desensitization would be unsafe. Admission threshold would be lower, the team would involve transplant infectious disease early, reduce modifiable immunosuppression only with the transplant team, and discuss the limited evidence for alternatives such as nitazoxanide or ciprofloxacin. That branch demonstrates why “sulfa allergy” must be characterized before illness becomes severe—and why there is no simple equivalent substitute.

Nuance: The case also illustrates the surveillance thesis. The outbreak did not arise because this clinician initially missed it, but every missed test delays the collective ability to define its magnitude and source. Absence from a dashboard—or from a routine O&P report—is not evidence of absence.

Tonight on Shift

1. Recognize the phenotype. During May through August, place Cyclospora on the differential for persistent or relapsing watery, nonbloody diarrhea with disproportionate fatigue, anorexia, bloating, or weight loss—even without international travel. Assess dehydration, renal function, electrolytes, immune status, and red flags that require a broader workup.

1. Order a test that contains the target. Verify that the local multiplex GI PCR panel includes C. cayetanensis, or explicitly request targeted Cyclospora PCR or microscopy with concentration, modified acid-fast staining, and/or UV autofluorescence. If microscopy is negative but suspicion remains high, submit specimens collected on separate days.

1. Treat thoughtfully and correctly. Collect stool before therapy when feasible, rehydrate and correct electrolytes, and use TMP-SMX DS 160/800 mg orally twice daily for 7–10 days in a typical immunocompetent adult. Individualize for renal function, pregnancy, interactions, immunocompromise, and the exact sulfonamide-allergy phenotype.

1. Avoid antibacterial noise. Do not rely on azithromycin, metronidazole, or broad enteric coverage for a protozoal cause. Use probability, severity, turnaround, immune status, and follow-up to decide whether to treat empirically. After a positive result, stop redundant agents and interpret relapse as a prompt to reassess—not proof of resistance.

1. Make the case traceable today. Report suspected or confirmed disease promptly according to local requirements. Record onset, travel, grocery and restaurant dates, specific produce and mixed dishes, brands, store locations, receipts, loyalty or delivery histories, packaging, and dining companions. Ask the laboratory to retain stool when public-health referral or genotyping may be useful.

1. Counsel without overpromising. State that the national food source remains unconfirmed; washing produce under running water reduces but does not eliminate risk; direct person-to-person spread is unlikely because oocysts must mature environmentally; and official product-specific advisories should guide avoidance. Tell patients that recurrent symptoms warrant reassessment and that participating in an interview may help prevent additional cases.

Read this seminar as Markdown · All seminars · Lecture library · Question bank